Amgen Inc (AMGN)
264.82
+0.78
(+0.30%)
USD |
NASDAQ |
Apr 18, 11:41
Amgen Research and Development Expense (Quarterly): 1.534B for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.534B |
| September 30, 2023 | 1.079B |
| June 30, 2023 | 1.113B |
| March 31, 2023 | 1.058B |
| December 31, 2022 | 1.324B |
| September 30, 2022 | 1.112B |
| June 30, 2022 | 1.039B |
| March 31, 2022 | 959.00M |
| December 31, 2021 | 1.348B |
| September 30, 2021 | 1.422B |
| June 30, 2021 | 1.082B |
| March 31, 2021 | 967.00M |
| December 31, 2020 | 1.229B |
| September 30, 2020 | 1.062B |
| June 30, 2020 | 964.00M |
| March 31, 2020 | 952.00M |
| December 31, 2019 | 1.312B |
| September 30, 2019 | 1.001B |
| June 30, 2019 | 924.00M |
| March 31, 2019 | 879.00M |
| December 31, 2018 | 1.182B |
| September 30, 2018 | 926.00M |
| June 30, 2018 | 869.00M |
| March 31, 2018 | 760.00M |
| December 31, 2017 | 1.043B |
| Date | Value |
|---|---|
| September 30, 2017 | 877.00M |
| June 30, 2017 | 873.00M |
| March 31, 2017 | 769.00M |
| December 31, 2016 | 1.078B |
| September 30, 2016 | 990.00M |
| June 30, 2016 | 900.00M |
| March 31, 2016 | 872.00M |
| December 31, 2015 | 1.093B |
| September 30, 2015 | 1.119B |
| June 30, 2015 | 964.00M |
| March 31, 2015 | 894.00M |
| December 31, 2014 | 1.234B |
| September 30, 2014 | 1.018B |
| June 30, 2014 | 1.018B |
| March 31, 2014 | 1.027B |
| December 31, 2013 | 1.249B |
| September 30, 2013 | 989.00M |
| June 30, 2013 | 967.00M |
| March 31, 2013 | 878.00M |
| December 31, 2012 | 938.00M |
| September 30, 2012 | 880.00M |
| June 30, 2012 | 826.00M |
| March 31, 2012 | 736.00M |
| December 31, 2011 | 851.00M |
| September 30, 2011 | 761.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
924.00M
Minimum
Jun 2019
1.534B
Maximum
Dec 2023
1.131B
Average
1.079B
Median
Sep 2023
Research and Development Expense (Quarterly) Benchmarks
| Gilead Sciences Inc | 1.408B |
| Johnson & Johnson | 4.48B |
| Eli Lilly and Co | 2.563B |
| Merck & Co Inc | 9.627B |
| Vertex Pharmaceuticals Inc | 824.60M |